We're proud to be acknowledged in Signify Research's Product Developments & Technology Trends report. The trends discussed in the report are set to shape the future of the AI market for the coming years. 

Find out more in this recent article The Technologies Making Moves in Medical Imaging AI, published in Health Tech Hot Spot

We're proud to be acknowledged in Signify Research's Product Developments & Technology Trends report.

The Technologies Making Moves in Medical Imaging AI

AI medical technology company Artrya Limited is announcing its partnership with leading global commercial services provider 

AI medical technology company Artrya Limited is announcing its partnership with leading global commercial services provider EVERSANA Life Sciences LLC.


Australian AI Company Artrya Announces Major UK Commercialisation Partnership with Eversana

The medical technology company listed today after raising $40 million at $1.35. Its share price is up ~13% to $1.52.

How did this week’s five IPOs perform?

Artrya has lodged a prospectus with ASIC with a view to list on the Australian Stock Exchange. This has offered investors an opportunity to buy into a business with a mission to save lives through better detection of heart disease. The funds from the IPO will go towards further research and development, as well as supporting international expansion in 2022. Read more about the commercialisation of our business:

Click here to read the article on Business News Australia

Artrya has lodged a prospectus with ASIC with a view to list on the Australian Stock Exchange.

Heart disease AI diagnostics med-tech Artrya to list at $105m valuation

Artrya's co-founder and Managing Director, John Barrington AM, recently took part in a Q&A with Stockhead. Read more about the significant market opportunity that Artrya is addressing with proprietary AI - for the benefit of patients, healthcare professionals and health systems around the world.

Click here to read the Q&A with Stockhead

Artrya's co-founder and Managing Director, John Barrington AM, recently took part in a Q&A with Stockhead.

Artrya MD John Barrington on next month’s listing and commercialising AI health tech

Artificial intelligence medical technology company Artrya (AYA) listed on the ASX today following the completion of its $40 million raise.

AI Medtech Artrya lists on stock exchange with market cap of $105M

Move over Appen, the new AI player in town went gangbusters on its first day as a public company.

New artificial intelligence ASX share rockets 13% on debut

Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack. Globally, we will change how the world sees coronary artery disease.

Click here to read the article in the Sydney Morning Herald

Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack.

From the heart: Pandemic no barrier for medtech’s ASX listing

Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.

Our SaaS product for the detection and diagnosis of coronary artery disease was announced as one of a select shortlist for the United Kingdom’s National Health Service Shared Business Services Limited Framework last month.

The Framework Agreement means 1250 hospitals and other health organisations across the UK will be able to purchase Artrya Salix with ease, simplifying procurement processes and pricing agreement. Artrya anticipates receiving the UKCA regulatory approval mid-2022, allowing commercial activity to commence.

This is another great milestone as we progress our mission to save lives from coronary artery disease through advanced detection technologies.

Artrya Salix is the only dedicated product focusing on coronary artery disease patient risk identification including the detection of vulnerable plaque and workflow optimisation.

We are listed in the ARTG in Australia, and have applied for Food and Drug Administration (FDA) regulatory clearance in the US and Health Canada clearance for the Canadian market.

Find out more about how Artrya Salix is bringing to market a 

Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.


Aussie AI diagnostics med-tech Artrya takes heart from new UK NHS status

A local player is Artrya, a start-up targeting heart disease. 

Led by co-founders John Barrington and John Konstantopoulos, managing director and executive director, respectively, the Artrya team is using AI to more accurately identify patients at risk of coronary artery disease. 

“John worked closely with IBM’s Watson health team globally, and my interest in technology has led me to believe that AI is fundamental to the future,” 

Mr Barrington said. “It’s that interest which has inspired us to find out how we can harness AI rapidly and develop technology for the good of humanity.” 

The pair met four years ago and spent 18 months researching the role ‘vulnerable plaque’ plays in heart disease. 

Vulnerable plaque causes unstable blockages in blood vessel walls. Artrya launched in May 2019 and, perhaps surprisingly in this competitive space, its fundraising efforts were oversubscribed each time they went to the market. 

In May, the company raised $15 million led by Bell Potter. Artrya’s team now includes Girish Dwivedi, a world-leading expert in vulnerable plaque and practising cardiologist, who was brought to WA by the Harry Perkins Institute of Medical Research. 

“Girish then introduced us to Abdul Ihdayhid, a cardiologist and leading researcher in coronary blood flow,” Mr Barrington told Business News. 

It was a perfect storm, he said, of brilliant minds brought together to keep the flywheel spinning. Artrya co-founder Mr Konstantopoulos said the statistics around heart disease were alarming.

“Sixty-four per cent of women and 50 per cent of men who die of heart attacks have no prior warning, and two thirds of those who die don’t exhibit significant narrowing of the arteries but do have build-up of vulnerable plaque,” he said. 

Artrya has created a diagnostic solution that can identify within minutes if vulnerable plaque is present, as well as assessing blood flow, without the need to insert a wire up through the thigh and into the heart. 

“The clinician can refer them to have a CT coronary angiogram, and from there, our AI ‘drives’ through each of the arteries, assessing faults and other problems,” Mr Konstantopoulos said. 

The work could contribute to saving lives in clinics globally. “Heart disease claims 18 million lives a year; it’s the biggest cause of death in the world,” Mr Barrington said. 

“That’s where we can contribute to society and create a high growth company in Perth, generating returns for our investors. Wherever the internet is available, you can diagnose using our technology.” 

Artrya is currently undergoing trials with Wembley based Envision Medical Imaging and is planning national pilots followed by a commercial rollout. 

“We’ve successfully concluded our third capital raising,” Mr Barrington said. 

“We intended to raise $10 million, and we had more than $30 million in applications; we closed at $15 million. 

“This technology is exponential; it’s accelerating at an increasing pace over time. 

“It’s hard to predict where it’ll go over the next 10 years, but the capability of AI will dramatically develop beyond our imagination.”

Several exciting AI innovations are emerging from WA, and the world is watching.

Researchers Eye Health Benefit From AI

https://www.afr.com/technology/perth-company-raises-15m-for-ai-software-to-transform-cardiac-imaging-20210520-p57tnu

A Perth-based medical technology company that tackles the world’s biggest killer, heart disease, with artificial intelligence-powered imaging software has raised $15 million from institutional investors.

Artrya, launched in May 2019 by former management consultant John Barrington and former IBM global industry leader John Konstantopoulos, says its software is a more accurate and less invasive way to detect signs of heart disease than other methods. It has raised the capital to support its commercialisation of the technology.

The $15 million has come from investors,including Alex Waislitz’s Thorney, Watermark Funds Management, Washington H. Soul Pattinson, Regal Funds Management and SG Hiscock.

Artrya’s technology, called Salix, analyses 

 in minutes and produces a 3D image and report that provides a more accurate detection of coronary artery disease, including the presence of vulnerable plaque, which is challenging to identify with existing technology.

It can also show the movement of blood through the heart, called a fractional flow reserve. However, it still needs to receive approval from the Therapeutic Goods Administration for this function. Traditionally fractional flow reserve is measured via coronary angiogram – a minimally invasive procedure in which contrast dye and x-ray imaging is used to detect blockages in the arteries.

Artrya raises $15m for AI software to transform cardiac imaging

AI-powered imaging software has raised $15 million from institutional investors

In this article, the Financial Review shares some information on our accomplishments, IPO and overall progress towards our goals. 

Cardiac imaging start-up Artrya raising $40m through an IPO

Fresh from its ASX debut, AYA’s mission is simple: it’s out to more accurately and less invasively detect signs of heart disease with the power of artificial intelligence (AI).

Artrya gets to the heart of AI with ASX listing, $40 million IPO

With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible. The priority and initial public offering closed on October 29th raising $40million to support further business acceleration. The team are now working through the finer details to list on the ASX and expect to finalise in the next few weeks.

Further interested investors are encouraged to follow our progress and buy on market in due course. 

With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible.

How to invest in the Artrya IPO

Artrya has been accepted onto the UK National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms.

Artrya Chief Medical Officer, Professor Girish Dwivedi, who previously spent time in the UK as a National Institute of Health Research Clinical Lecturer in Cardiovascular Medicine at the University of Birmingham discusses how the recognition as a UK preferred supplier is an important milestone for Salix.

“This is an international endorsement of Salix’s clinical credentials, and testament to the quality of the Salix product and our world-class technical team,” Professor Dwivedi said.


Artrya has been accepted onto the UK National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms.﻿

UK preferred supplier status for Australian AI company Artrya

Local medtech Artya has listed on the stock exchange, having earlier raised $40 million through an IPO to help commercialise its cardiac imaging software.

Artrya rises on ASX debut

Crawley-based Artrya has been shortlisted as a preferred supplier of AI Software by the UK Health Service for its heart disease detection program. 

Medtech Artrya breaks into UK market

In this Stockhead article, Tim Boreham dives into Artrya as a company and shares his thoughts in the current $100M market valuation. He also speaks on Artya's recent accomplishments as well as goals in the months and years to come. 

Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system

After closing our initial public offering (IPO), the Motley Fool shares details on Artrya's AI technology and how it could disrupt the detection of coronary artery disease for years to come. 

Move over Appen: A new artificial intelligence stock to list on the ASX

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering (IPO).

Cardiac imaging software company Artrya (ASX:AYA) up on public debut

https://www.uwa.edu.au/news/Article/2021/May/Artificial-intelligence-to-predict-heart-disease

Industry News & Updates

RECENT MEDIA HIGHLIGHTS AND ANNOUNCEMENTS